Incyte Corporation (INCY) News

Incyte Corporation (INCY)

Today's Latest Price: $85.39 USD

1.40 (-1.61%)

Updated Sep 21 6:55pm

Add INCY to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 373 in Biotech

See all "A" rated Strong Buy stocks

Filter INCY News Items

INCY News Results

Event/Time Symbol Company News Detail Start End Change POWR Rating
Loading, please wait...

Latest INCY News From Around the Web

Below are the latest news stories about Incyte Corp that investors may wish to consider to help them evaluate INCY as an investment opportunity.

Lilly and Pfizer Are Testing Treatments for Hospitalized Covid Patients

Lilly’s anti-inflammatory drug Olumiant reduced hospital stays when combined with Gilead’s remdesivir.

Yahoo | September 16, 2020

Incyte Corporation (INCY) Fell Out Of Favor With Hedge Funds

Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the second quarter. You can find articles about an individual hedge fund's trades on numerous financial […]

Yahoo | September 16, 2020

Baricitinib in Combination with Remdesivir Reduces Time to Recovery in Hospitalized Patients with COVID-19 in NIAID-Sponsored ACTT-2 Trial

INDIANAPOLIS, Sept. 14, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today initial data emerging from the Adaptive COVID-19 Treatment Trial (ACTT-2) sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the…

PR Newswire | September 14, 2020

Gilead Makes Its Biggest Buy Ever And Gets A 'Flagship' Cancer Drug

Gilead Sciences drew mixed reactions from analysts after the company announced its largest acquisition ever, gaining a possible flagship cancer treatment. GILD stock rose on the news.

Yahoo | September 14, 2020

Eli Lilly, Incyte Combine Covid Drug With Gilead's, Post Positive Data

Eli Lilly and Incyte released positive initial data of their coronavirus treatment when combined with Gilead's remdesivir and said they would seek emergency use authorization from the FDA.

Yahoo | September 14, 2020

Balloons at Macy’s Thanksgiving Day Parade Will Be Rigged to Special Vehicles

FEATURE Here’s what you need to know about the impact of Covid-19 to navigate the markets today. • This year’s Macy’s Thanksgiving Day Parade will be a TV-only event, with in-person viewing discouraged and big changes to the procession.

Yahoo | September 14, 2020

Shares of Lilly and Incyte gain after late-stage study finds their arthritis drug can help reduce COVID-19 recovery time

Eli Lily & Co. and Incyte Corp. said Monday that their rheumatoid arthritis drug Olumiant helped reduce recovery time in hospitalized COVID-19 patients when it was used in combination with Gilead Sciences Inc.'s remdesivir. Shares of Lily gained 0.7% in premarket trading on Monday, while Incyte's stock was up 1.4% and shares of Gilead were down 2.1%. The Food and Drug Administration (FDA) earlier this year authorized remdesivir as a treatment for some hospitalized COVID-19 patients, though the drug has not received a full approval at this time. A number of clinical trials are underway that are testing remdesivir in combination with other therapies, including Olumiant. The Phase 3, double-blind, randomized, controlled study testing Olumiant and remdesivir in 1,000 patients was...

Yahoo | September 14, 2020

Incyte Announces Recipient of the Inaugural Incyte Ingenuity Award to Recognize Innovative Solutions that Address Needs in the GVHD Community

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that Massachusetts General Cancer Center is the recipient of the first Incyte Ingenuity Award, an annual program that was created to support people living with graft-versus-host disease (GVHD) by encouraging innovative and novel solutions that address specific challenges facing the GVHD community. Massachusetts General Cancer Center has been awarded $100,000 to implement its project, Horizon Mobile App for Patients with Chr

Business Wire | September 9, 2020

Incyte (INCY) Down 2.2% Since Last Earnings Report: Can It Rebound?

Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | September 3, 2020

Incyte Announces Pivotal GEOMETRY mono-1 Study Results of Capmatinib (Tabrecta™) in Patients with METex14 Metastatic Non-Small Cell Lung Cancer Published in NEJM

Pivotal GEOMETRY mono-1 Study Results of Capmatinib (Tabrecta™) in Patients with METex14 Metastatic Non-Small Cell Lung Cancer Published in NEJM

Yahoo | September 2, 2020

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7081 seconds.